Trial Profile
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Jun 2023 Results (n=11)assessing biological impact of immunotherapy in SCLC , presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Mar 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.